Sequoia Financial Advisors LLC Acquires 11,505 Shares of Sanofi $SNY

Sequoia Financial Advisors LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 45.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,712 shares of the company’s stock after purchasing an additional 11,505 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,769,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Hudson Bay Capital Management LP acquired a new stake in shares of Sanofi during the third quarter worth $6,243,000. Aberdeen Group plc boosted its stake in Sanofi by 22.7% in the 4th quarter. Aberdeen Group plc now owns 467,241 shares of the company’s stock worth $22,642,000 after purchasing an additional 86,314 shares during the period. Benson Investment Management Company Inc. bought a new position in Sanofi during the 4th quarter worth about $5,424,000. Euro Pacific Asset Management LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at about $2,111,000. Finally, Assetmark Inc. raised its stake in shares of Sanofi by 24.2% in the 4th quarter. Assetmark Inc. now owns 443,668 shares of the company’s stock valued at $21,500,000 after purchasing an additional 86,496 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.2%

Shares of SNY opened at $43.68 on Thursday. The firm has a 50 day simple moving average of $43.30 and a two-hundred day simple moving average of $45.56. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. Sanofi has a one year low of $40.89 and a one year high of $52.68. The company has a market cap of $105.90 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.10 and a beta of 0.34.

Analysts Set New Price Targets

SNY has been the subject of several recent research reports. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Monday, April 20th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $49.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.